Fig. 5

DNA methylation patterns of EBF3 and TBC1D16 CpG dinucleotides in a whole genome bisulfite sequencing (WGBS) cohort of primary tumours. These TCGA WGBS data consist of 46 primary tumour samples for urothelial bladder carcinoma (BLCA, n = 7), breast invasive carcinoma (BRCA, n = 5), colon adenocarcinoma (COAD, n = 3), glioblastoma multiforme (GBM, n = 6), lung adenocarcinoma (LUAD, n = 6), lung squamous cell carcinoma (LUSC, n = 5), rectum adenocarcinoma (READ, n = 3), stomach adenocarcinoma (STAD, n = 5) and uterine corpus endometrial carcinoma (UCEC, n = 6). a The upper panel shows ten CpG loci in the EBF3 promoter identified as differentially methylated between primary and metastatic melanoma by Chatterjee et al. [9]. b The middle panel shows DNA methylation patterns of seven CpG sites in the gene body of EBF3, which were identified as differentially methylated between benign nevi, primary melanomas and metastases by Wouters et al. [10]. c The bottom panel shows a combination of five CpG sites in the gene body of TBC1D16 that Vizoso et al. [13] and Wouters et al. [10] showed as differentially methylated between primary and metastatic tumours. Low to high methylation is shown as a continuous variable from blue (0) to white (0.5) to red (1)